References analysis of the Wikipedia article "CD19" in the English version

doi.org

Tedder TF, Isaacs CM (July 1989). "Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily". Journal of Immunology. 143 (2): 712–717. doi:10.4049/jimmunol.143.2.712. PMID 2472450. S2CID 22081793.

Scheuermann RH, Racila E (August 1995). "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy". Leukemia & Lymphoma. 18 (5–6): 385–397. doi:10.3109/10428199509059636. PMID 8528044.

Merville P, Déchanet J, Desmoulière A, Durand I, de Bouteiller O, Garrone P, et al. (January 1996). "Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts". The Journal of Experimental Medicine. 183 (1): 227–236. doi:10.1084/jem.183.1.227. PMC 2192413. PMID 8551226.

Martín P, Santón A, Bellas C (April 2004). "Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis". Histopathology. 44 (4): 375–380. doi:10.1111/j.1365-2559.2004.01834.x. PMID 15049904. S2CID 45937555.

Wang K, Wei G, Liu D (November 2012). "CD19: a biomarker for B cell development, lymphoma diagnosis and therapy". Experimental Hematology & Oncology. 1 (1): 36. doi:10.1186/2162-3619-1-36. PMC 3520838. PMID 23210908.

Zhou LJ, Ord DC, Omori SA, Tedder TF (1992). "Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes". Immunogenetics. 35 (2): 102–111. doi:10.1007/bf00189519. PMID 1370948. S2CID 7182703.

Mei HE, Schmidt S, Dörner T (November 2012). "Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity". Arthritis Research & Therapy. 14 Suppl 5 (Suppl 5): S1. doi:10.1186/ar3909. PMC 3535716. PMID 23281743.

Haas KM, Tedder TF (2005). "Role of the CD19 and CD21/35 Receptor Complex in Innate Immunity, Host Defense and Autoimmunity". Mechanisms of Lymphocyte Activation and Immune Regulation X. Advances in Experimental Medicine and Biology. Vol. 560. Boston, MA: Springer. pp. 125–139. doi:10.1007/0-387-24180-9_16. ISBN 978-0-387-24188-3. PMID 15934172.

Tedder TF (October 2009). "CD19: a promising B cell target for rheumatoid arthritis". Nature Reviews. Rheumatology. 5 (10): 572–577. doi:10.1038/nrrheum.2009.184. PMID 19798033. S2CID 6143992.

Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC (2005). "CD19 function in central and peripheral B-cell development". Immunologic Research. 31 (2): 119–131. doi:10.1385/IR:31:2:119. PMID 15778510. S2CID 45145420.

Carter RH, Wang Y, Brooks S (2002). "Role of CD19 signal transduction in B cell biology". Immunologic Research. 26 (1–3): 45–54. doi:10.1385/IR:26:1-3:045. PMID 12403344. S2CID 35818699.

Otero DC, Anzelon AN, Rickert RC (January 2003). "CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals". Journal of Immunology. 170 (1): 73–83. doi:10.4049/jimmunol.170.1.73. PMID 12496385.

Sato S (December 1999). "CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity". Journal of Dermatological Science. 22 (1): 1–10. doi:10.1016/s0923-1811(99)00043-2. PMID 10651223.

Rickert RC, Rajewsky K, Roes J (July 1995). "Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice". Nature. 376 (6538): 352–355. Bibcode:1995Natur.376..352R. doi:10.1038/376352a0. PMID 7543183. S2CID 4337673.

Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF (July 1995). "Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule". Immunity. 3 (1): 39–50. doi:10.1016/1074-7613(95)90157-4. PMID 7542548.

Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A (June 2012). "CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis". The Journal of Clinical Investigation. 122 (6): 2257–2266. doi:10.1172/jci45851. PMC 3366393. PMID 22546857.

Monroe JG (April 2006). "ITAM-mediated tonic signalling through pre-BCR and BCR complexes". Nature Reviews. Immunology. 6 (4): 283–294. doi:10.1038/nri1808. PMID 16557260. S2CID 28197010.

Maier H, Ostraat R, Parenti S, Fitzsimmons D, Abraham LJ, Garvie CW, et al. (October 2003). "Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP)". Nucleic Acids Research. 31 (19): 5483–5489. doi:10.1093/nar/gkg785. PMC 206479. PMID 14500810.

Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF (September 2012). "A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice". Journal of Immunology. 189 (5): 2318–2325. doi:10.4049/jimmunol.1201000. PMC 3426298. PMID 22826319.

Morbach H, Schickel JN, Cunningham-Rundles C, Conley ME, Reisli I, Franco JL, et al. (March 2016). "CD19 controls Toll-like receptor 9 responses in human B cells". The Journal of Allergy and Clinical Immunology. 137 (3): 889–98.e6. doi:10.1016/j.jaci.2015.08.040. PMC 4783287. PMID 26478008.

Pesando JM, Bouchard LS, McMaster BE (December 1989). "CD19 is functionally and physically associated with surface immunoglobulin". The Journal of Experimental Medicine. 170 (6): 2159–2164. doi:10.1084/jem.170.6.2159. PMC 2189531. PMID 2479707.

van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, et al. (May 2006). "An antibody-deficiency syndrome due to mutations in the CD19 gene". The New England Journal of Medicine. 354 (18): 1901–1912. doi:10.1056/nejmoa051568. PMID 16672701.

Carsetti R, Valentini D, Marcellini V, Scarsella M, Marasco E, Giustini F, et al. (March 2015). "Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndrome". European Journal of Immunology. 45 (3): 903–914. doi:10.1002/eji.201445049. PMC 4674966. PMID 25472482.

Verstegen RH, Driessen GJ, Bartol SJ, van Noesel CJ, Boon L, van der Burg M, et al. (December 2014). "Defective B-cell memory in patients with Down syndrome". The Journal of Allergy and Clinical Immunology. 134 (6): 1346–1353.e9. doi:10.1016/j.jaci.2014.07.015. PMID 25159464.

Seckin AN, Ozdemir H, Ceylan A, Artac H (February 2018). "Age-related alterations of the CD19 complex and memory B cells in children with Down syndrome". Clinical and Experimental Medicine. 18 (1): 125–131. doi:10.1007/s10238-017-0457-2. PMID 28197808. S2CID 19318246.

Fujimoto M, Sato S (April 2007). "B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity". Journal of Dermatological Science. 46 (1): 1–9. doi:10.1016/j.jdermsci.2006.12.004. hdl:2297/3661. PMID 17223015. S2CID 9666705.

Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (March 2011). "Long-lived autoreactive plasma cells drive persistent autoimmune inflammation". Nature Reviews. Rheumatology. 7 (3): 170–178. doi:10.1038/nrrheum.2011.1. PMID 21283146. S2CID 43750896.

Porter DL, Levine BL, Kalos M, Bagg A, June CH (August 2011). "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia". The New England Journal of Medicine. 365 (8): 725–733. doi:10.1056/nejmoa1103849. PMC 3387277. PMID 21830940.

Sadelain M (December 2017). "CD19 CAR T Cells". Cell. 171 (7): 1471. doi:10.1016/j.cell.2017.12.002. PMID 29245005.

Velasquez MP, Gottschalk S (January 2017). "Targeting CD19: the good, the bad, and CD81". Blood. 129 (1): 9–10. doi:10.1182/blood-2016-11-749143. PMC 5216268. PMID 28057672.

nih.gov

pubmed.ncbi.nlm.nih.gov

Scheuermann RH, Racila E (August 1995). "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy". Leukemia & Lymphoma. 18 (5–6): 385–397. doi:10.3109/10428199509059636. PMID 8528044.

Tedder TF (October 2009). "CD19: a promising B cell target for rheumatoid arthritis". Nature Reviews. Rheumatology. 5 (10): 572–577. doi:10.1038/nrrheum.2009.184. PMID 19798033. S2CID 6143992.

Carter RH, Wang Y, Brooks S (2002). "Role of CD19 signal transduction in B cell biology". Immunologic Research. 26 (1–3): 45–54. doi:10.1385/IR:26:1-3:045. PMID 12403344. S2CID 35818699.

Monroe JG (April 2006). "ITAM-mediated tonic signalling through pre-BCR and BCR complexes". Nature Reviews. Immunology. 6 (4): 283–294. doi:10.1038/nri1808. PMID 16557260. S2CID 28197010.

Sadelain M (December 2017). "CD19 CAR T Cells". Cell. 171 (7): 1471. doi:10.1016/j.cell.2017.12.002. PMID 29245005.

Velasquez MP, Gottschalk S (January 2017). "Targeting CD19: the good, the bad, and CD81". Blood. 129 (1): 9–10. doi:10.1182/blood-2016-11-749143. PMC 5216268. PMID 28057672.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

Tedder TF (October 2009). "CD19: a promising B cell target for rheumatoid arthritis". Nature Reviews. Rheumatology. 5 (10): 572–577. doi:10.1038/nrrheum.2009.184. PMID 19798033. S2CID 6143992.

Carter RH, Wang Y, Brooks S (2002). "Role of CD19 signal transduction in B cell biology". Immunologic Research. 26 (1–3): 45–54. doi:10.1385/IR:26:1-3:045. PMID 12403344. S2CID 35818699.

Monroe JG (April 2006). "ITAM-mediated tonic signalling through pre-BCR and BCR complexes". Nature Reviews. Immunology. 6 (4): 283–294. doi:10.1038/nri1808. PMID 16557260. S2CID 28197010.

CD19 (English Wikipedia)

clinicaltrials.gov

doi.org

ensembl.org

May2017.archive.ensembl.org

handle.net

hdl.handle.net

harvard.edu

ui.adsabs.harvard.edu

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nii.ac.jp

kanazawa-u.repo.nii.ac.jp

semanticscholar.org

api.semanticscholar.org

worldcat.org

search.worldcat.org